The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm

Don L. Gibbons, Sabrina Pricl, Hagop Kantarjian, Jorge Cortes, Alfonso Quintás-Cardama

Research output: Contribution to journalComment/debate

Abstract

The use of tyrosine kinase inhibitors (TKIs) has become an integral component of cancer therapy. Imatinib mesylate, a breakpoint cluster region-Abelson BCR-ABL1 inhibitor, was the first TKI approved in cancer medicine and has served as a model for the development of similar agents for other cancers. An important drawback of TKI therapy is the development of resistance, frequently through the acquisition of mutations. Mutations at the gatekeeper residues of BCR-ABL1 (eg, the threonine-to-isoleucine mutation at codon 315) and other oncogenic kinases have proven highly resistant to currently available TKIs. Advances in the structural biology of oncogenic kinases have facilitated the rational development of TKIs that are active against gatekeeper mutations.

Original languageEnglish (US)
Pages (from-to)293-299
Number of pages7
JournalCancer
Volume118
Issue number2
DOIs
StatePublished - Jan 15 2012
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Mutation
Phosphotransferases
Neoplasms
Isoleucine
Threonine
Codon
Medicine
Therapeutics

Keywords

  • Chronic myeloid leukemia
  • Gatekeeper mutation
  • Ponatinib
  • Threonine-to-isoleucine mutation at codon 315
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gibbons, D. L., Pricl, S., Kantarjian, H., Cortes, J., & Quintás-Cardama, A. (2012). The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer, 118(2), 293-299. https://doi.org/10.1002/cncr.26225

The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. / Gibbons, Don L.; Pricl, Sabrina; Kantarjian, Hagop; Cortes, Jorge; Quintás-Cardama, Alfonso.

In: Cancer, Vol. 118, No. 2, 15.01.2012, p. 293-299.

Research output: Contribution to journalComment/debate

Gibbons, DL, Pricl, S, Kantarjian, H, Cortes, J & Quintás-Cardama, A 2012, 'The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm', Cancer, vol. 118, no. 2, pp. 293-299. https://doi.org/10.1002/cncr.26225
Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintás-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15;118(2):293-299. https://doi.org/10.1002/cncr.26225
Gibbons, Don L. ; Pricl, Sabrina ; Kantarjian, Hagop ; Cortes, Jorge ; Quintás-Cardama, Alfonso. / The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. In: Cancer. 2012 ; Vol. 118, No. 2. pp. 293-299.
@article{6846db91539e45c687f019611b1fc9e9,
title = "The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm",
abstract = "The use of tyrosine kinase inhibitors (TKIs) has become an integral component of cancer therapy. Imatinib mesylate, a breakpoint cluster region-Abelson BCR-ABL1 inhibitor, was the first TKI approved in cancer medicine and has served as a model for the development of similar agents for other cancers. An important drawback of TKI therapy is the development of resistance, frequently through the acquisition of mutations. Mutations at the gatekeeper residues of BCR-ABL1 (eg, the threonine-to-isoleucine mutation at codon 315) and other oncogenic kinases have proven highly resistant to currently available TKIs. Advances in the structural biology of oncogenic kinases have facilitated the rational development of TKIs that are active against gatekeeper mutations.",
keywords = "Chronic myeloid leukemia, Gatekeeper mutation, Ponatinib, Threonine-to-isoleucine mutation at codon 315, Tyrosine kinase inhibitor",
author = "Gibbons, {Don L.} and Sabrina Pricl and Hagop Kantarjian and Jorge Cortes and Alfonso Quint{\'a}s-Cardama",
year = "2012",
month = "1",
day = "15",
doi = "10.1002/cncr.26225",
language = "English (US)",
volume = "118",
pages = "293--299",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm

AU - Gibbons, Don L.

AU - Pricl, Sabrina

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Quintás-Cardama, Alfonso

PY - 2012/1/15

Y1 - 2012/1/15

N2 - The use of tyrosine kinase inhibitors (TKIs) has become an integral component of cancer therapy. Imatinib mesylate, a breakpoint cluster region-Abelson BCR-ABL1 inhibitor, was the first TKI approved in cancer medicine and has served as a model for the development of similar agents for other cancers. An important drawback of TKI therapy is the development of resistance, frequently through the acquisition of mutations. Mutations at the gatekeeper residues of BCR-ABL1 (eg, the threonine-to-isoleucine mutation at codon 315) and other oncogenic kinases have proven highly resistant to currently available TKIs. Advances in the structural biology of oncogenic kinases have facilitated the rational development of TKIs that are active against gatekeeper mutations.

AB - The use of tyrosine kinase inhibitors (TKIs) has become an integral component of cancer therapy. Imatinib mesylate, a breakpoint cluster region-Abelson BCR-ABL1 inhibitor, was the first TKI approved in cancer medicine and has served as a model for the development of similar agents for other cancers. An important drawback of TKI therapy is the development of resistance, frequently through the acquisition of mutations. Mutations at the gatekeeper residues of BCR-ABL1 (eg, the threonine-to-isoleucine mutation at codon 315) and other oncogenic kinases have proven highly resistant to currently available TKIs. Advances in the structural biology of oncogenic kinases have facilitated the rational development of TKIs that are active against gatekeeper mutations.

KW - Chronic myeloid leukemia

KW - Gatekeeper mutation

KW - Ponatinib

KW - Threonine-to-isoleucine mutation at codon 315

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84855503769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855503769&partnerID=8YFLogxK

U2 - 10.1002/cncr.26225

DO - 10.1002/cncr.26225

M3 - Comment/debate

C2 - 21732333

AN - SCOPUS:84855503769

VL - 118

SP - 293

EP - 299

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -